[{"Assets_0_Q3_USD":268788000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":14276000.0,"NetIncomeLoss_1_Q3_USD":14040000.0,"NetIncomeLoss_3_Q3_USD":19313000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":15483037.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":15482768.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":15011159.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":14903945.0,"StockholdersEquity_0_Q3_USD":194065000.0,"EarningsPerShareBasic_1_Q3_USD":0.94,"EarningsPerShareBasic_3_Q3_USD":1.3,"EarningsPerShareDiluted_1_Q3_USD":0.91,"EarningsPerShareDiluted_3_Q3_USD":1.25,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":51337000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":157258000.0,"Ticker":"EGRX","CIK":"827871","name":"EAGLE PHARMACEUTICALS, INC.","OfficialName":"Eagle Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"635235963.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181101"}]